Preliminary Results of Betulinic Acid-Loaded Magnetoliposomes - a Potential Approach to Increase Therapeutic Efficacy in Melanoma

CLAUDIA GEANINA FARCAS1,2, ELENA ALINA MOACA1,2, RAZVAN DRAGO1,2, DELIA BERCEANU VADUVA3, IASMINA MARCOCVICI1, CIPRIAN VALENTIN MIHALI1, FELICIA LOGHIN2

1Victor Babes University of Medicine and Pharmacy Timisoara, Faculty of Pharmacy, 2 Eftimie Murgu Sq., 300041, Romania
2Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Faculty of Pharmacy, Dept of Toxicology, 8 Victor Babes Str., 400012, Cluj-Napoca, Romania
3Victor Babes University of Medicine and Pharmacy Timisoara, Faculty of Pharmacy, 2 Eftimie Murgu Sq., 300041, Romania
4Vasile Goldis Western University of Arad, Institute of Life Sciences, George Emil Palade Electron Microscopy Center, 86 Liviu Rebreanu Str., 310414, Romania

Magnetoliposomes were placed into the biomedical spotlight due to their unique structure, preserving also magnetic features valuable for biomedical applications. The present study provides a preliminary evidence of the cytotoxicity induced by betulinic acid-loaded magnetoliposomes (BA-Fe3O4@Lip) on two melanoma cell lines - A375 and B164A5 cells and one healthy cell line - mice epidermis JB6 Cl 41-5a cells, augmented by references to potential biomedical applications. BA-Fe3O4@Lip showed significant cytotoxicity on the melanoma cell lines, compared with the blank liposomal structures. In addition, the healthy cell line displayed good viability rate after exposure to BA-Fe3O4@Lip.

Keywords: betulinic acid, thermosensitive magnetoliposomes, cytotoxicity, melanoma cells

**Betulinic acid** (BA) is a pentacyclic triterpene natural compound possessing a lupan structure [1,2] that has been proved to exhibit multiple therapeutic properties: selective antitumor activity, displaying minimal cytotoxic potential on healthy cells [3,4]; anti-HIV-1 (human immunodeficiency virus type-1) activity [5]; antimalarial and anti-inflammatory effect [6,7], anti-angiogenic potential [8,9], antibacterial and anthelmintic activity [6], augmented by its antioxidant capacity [10], being considered a compound with an important therapeutic potential.

Despite all these features, BA possesses a major inconvenience due to its low solubility in the biological hydrophilic medium, leading to poor bioavailability [11]. Derivatization of two key positions of the chemical structure of BA, marked red in figure 1 - C3 hydroxyl, C28 carboxyl, has been shown to potentiate the cytotoxic effect of BA and even increase its hydrophilicity, thus enhancing its bioavailability. However, the purification process of these derivatives is difficult to achieve [12].

![Fig. 1. Chemical structure of Betulinic acid; BA - 3β, hydroxy-lup-20(29)-en-28-oic acid; C3 hydroxyl, C28 carboxyl are marked in red.](http://www.revistadechimie.ro)

In the last years, several types of formulations have been developed to improve the bioavailability of BA, such as: BA nanoemulsion [9], incorporation of BA into cyclodextrins [13], cocrystals formation of BA and vitamin C [14], incorporation of BA into liposomes [15], BA functionalized carbon nanotubes [16], thus this topic has become of great interest among researchers around the world.

Liposomes embedding nanoparticles with magnetic properties (MNPs) are generically entitled magnetoliposomes [17]. Due to superparamagnetic features, MNPs can be used for magnetically induced hyperthermia, as drug delivery tools, or as magnetic resonance imaging (MRI) agents [18], hence the magnetoliposome platform can also benefit from the aforementioned features [17]. Among all MNPs, the most commonly used structure is Fe3O4 – magnetite (part of the iron oxide magnetic nanoparticles group - IOMNPs) due to its biocompatibility, high saturation magnetization and good colloidal stability if the surface is properly coated [19]. The use of a coating agent is necessary because due to their large surface area to volume ratio, van der Walls forces and/or by application of an external magnetic field, IOMNPs can agglomerate leading to large cluster formation [20].

However, to the best of our knowledge, no study has so far reported the incorporation of BA within magnetoliposome structure. This new formulation would not only improve BA’s bioavailability but could offer new therapeutic approaches as an alternative to the classical chemotherapy, by merging BA therapeutic activity with the superparamagnetic behaviour of IOMNPs. In this study, Fe3O4 nanoparticles coated with citric acid (Fe3O4@CA) were used for the synthesis of magnetoliposomes. Through the coating process, nanoparticles have acquired hydrophilicity and colloidal stability, possessing a hydrodynamic diameter of 101 nm (data not shown), thus overcoming undesirable effects that are characteristic of uncoated nanoparticles: agglomeration and rapid elimination by macrophages.

Herein, we present the development of a magnetoliposome structure that incorporates BA into the phospholipid bilayer and Fe3O4@CA into the aqueous core.
The preliminary results of the effects induced by the magnetoliposome platform, as well as the blank liposomal structures, on two melanoma cell lines (murine melanoma B164A5 cells and human melanoma A375 cells) and one healthy cell line (mice epidermis JB 6 Cl 41-5a cells) are also discussed.

The aim of the study is to provide basis information regarding development of smart multifunctional systems, such as magnetically-guided magnetoliposomes which can be controlled to reach the tumour site by applying an alternating magnetic field (AMF) followed by magnetically induced hyperthermia - able to alter the structure of colloidal suspension based on iron oxide magnetic (Lip) was magnetic stirring at 45°C and the biocompatible colloidal suspension.

Experimental part

Materials and methods

Reagents and cell lines

Betulinic acid (Lot # BCBW1969), L-α-Phosphatidylcoline from soybean (Lot # SLBT0172), Cholesterol from sheep wool and Polyethylene glycol 2000 (PEG-2000) were supplied from Sigma-Aldrich (Munich, Germany). Cell culture media, high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) and Eagle’s Minimum Essential Medium (EMEM) were purchased from ATCC.

The cell lines used in this study JB6 Cl 41-5a (ATCC® CRL-2010®) and A375 (ATCC® CRL-1619) were acquired from American Type Culture Collection (ATCC) and B164A5 vial (code 94042254) was purchased from Sigma-Aldrich (Munich, Germany). All the cell lines were maintained in standard conditions (liquid nitrogen) until the experiments begun.

Preparation of magnetic iron oxide nanoparticles (IONMPs)

The IOMNPs were synthesized using the combustion method [21] using iron nitrate nonahydrate (Fe(NO3)3·9H2O - as the oxidizing agent and citric acid monohydrated C6H8O7·H2O - as reducing agent. The obtained powder was hand ground, washed with hot distilled water (60-70°C) and dried. The dried Fe3O4 nanoparticles were coated with citric acid (CA) and then dispersed in water at basic pH thus obtained the biocompatible colloidal suspension.

Preparation of betulinic acid-loaded magnetoliposomes (BA-Fe3O4@Lip) were obtained by preparing a blank liposomal solution (Lip) of 0.1 mM lipid mixture using the lipid film hydration method [22]. The lipid mixture was composed of hydrogenated soybean phosphatidylcholine (HSPC), cholesterol and PEG-2000 in a molar ratio 90:10:0.4 and dissolved in chloroform by magnetic stirring at 40°C for 1 h, followed by drying at oven (40°C) overnight. Afterwards, the lipid film was hydrated with ultrapure water containing (NH4)2SO4. For the synthesis of blank magnetoliposomes (Fe3O4@Lip) an amount of filtered liposomal suspension (Lip) with a chloroform solution of betulinic acid (BA) to a final concentration equivalent to magnetic colloidal suspension ratio was 4:1, according to the study of Kulshrestha and co-workers [23]. Finally, BA-Fe3O4@Lip sample was obtained by mixing an amount of liposomal suspension (Lip) with a chloroform solution based on betulinic acid (10.1 m/L). After that, the colloidal suspension of Fe3O4@CA was dropwise added (4:1 v/v) [23]. All liposomal suspensions were shocked for 1h using a Q Sonica ultrasound device, at 50% amplitude. After sonication, samples were centrifuged at 4°C for 10 min at 6000 rpm for 5 times, re-suspended in ultrapure water and shocked for 10 min at 50% amplitude. After that, the liposomal suspensions were filtered once through a hydrophilic membrane of 220 nm, and stored at 4°C until further use.

No instability signs (flocclusion/agglomeration) were observed for almost one month if stored in appropriate conditions (4°C).

Characterization of BA-Fe3O4@Lip

Thermal analysis

To determine the phase transition temperature of BA-Fe3O4@Lip the sample was placed in aluminum crucibles under artificial air flow of 20 mL/min, and thermally scanned from 25 - 1000 °C at a heating rate of 10 °C/min using a TG/DSC thermal analyzer (Netzsch STA 449 C instrument (Selb, Germany).

Structural characterization

Scanning electron microscopy (SEM) was employed to evaluate the morphology of BA-Fe3O4@Lip and the energy dispersive X-ray analysis (EDAX) was used in order to obtain the elemental composition of the sample. SEM-EDAX analysis was carried out with EDX detection on scanning electron microscope (SEM), using an EDAX detector (ZAF Quantification-Standardless, Element Normalized) with FEI Quanta 250 microscope (Eindhoven, Holland).

Cell viability evaluation by the means of AlamarBlue (AB) assay

Assessment of the cytotoxic potential of test samples was performed as previously described [24]. 1x106 cells/well were seeded in 96-well plates and incubated overnight. The next day, the old medium was replaced with a fresh one containing the test compounds (Lip, Fe3O4@Lip, BA-Fe3O4@Lip and BA) to a final concentration equivalent to 5 and 25µM BA. BA dissolved in DMSO was also tested and was used as a positive control. After a period of 24/48 h of stimulation, 20 µL AlamarBlue solution (AB - 0.01%) was added in each well and incubated for 3h. In the final step, the absorbance of the wells was determined at 570 nm and 600 nm wavelengths, with a microplate reader (xMark Microplate, Biorad).

Cell morphology assessment

The morphological alterations induced by test samples on the three cell lines (JB6 Cl 41-5a, A375, B164A5) were assessed by taking pictures of the cells stimulated with the test compounds, at different intervals of time with an inverted Olympus IX73 microscope documented with an integrated DP74 camera (Olympus, Tokyo, Japan). The most severe morphological changes were observed 24h post-stimulation and are presented in fig. 5-7.

Statistical analysis

The statistical program used in this study was GraphPad Prism 5. Bar graphs are expressed as the mean values ± SD of three independent experiments. One-way ANOVA test followed by Tukey’s post-test were employed to determine the statistical differences between experimental and control groups (* p <0.05; ** p<0.01; *** p<0.001)

Results and discussion

Physio-chemical characterization of BA-Fe3O4@Lip

Thermogravimetric (TG) and differential scanning calorimetry (DSC)

Thermal analysis and phase transition temperature of BA-Fe3O4@Lip are depicted in figure 2. From the graph, it can be observed that the phase transition of BA-Fe3O4@Lip from gel to liquid crystalline occurred at 39.437°C. This temperature could be achieved in vitro or in vivo by using...
Fe₃O₄ nanoparticles as tools for inducing mild hyperthermia, following exposure to an external magnetic field due to magnetic hysteresis loss [18]. In the phase transition, the release of BA from the liposome nanosphere may emerge. Thus, it could be stated that the release of BA could be thermally controlled.

**Structural characterization**

The EDAX analysis showed that only C, O, N, P, S and Fe were present in the sample (table 1). The resulting chemical species in EDAX analysis were expressed in weight percent (Wt %) or atomic percent (At %).

| Element | Wt%  | At%  | K-Ratio | Z    | A     | F     |
|---------|------|------|---------|------|-------|-------|
| C       | 49.35| 56.67| 0.2153  | 1.0077| 0.4311| 1.0004|
| N       | 9.87 | 9.68 | 0.0115  | 1.0003| 0.1164| 1.0007|
| O       | 37.82| 32.47| 0.0551  | 0.9936| 0.1466| 1.0000|
| P       | 0.74 | 0.33 | 0.0033  | 0.9285| 0.7687| 1.0022|
| S       | 1.91 | 0.82 | 0.0180  | 0.9535| 0.8772| 1.0000|
| Fe      | 0.11 | 0.03 | 0.0010  | 0.8381| 1.0872| 1.0000|
| Total   | 100.00| 100.00|         |       |       |       |

By scanning electron microscopy -SEM (fig. 3) it has been established the details regarding the morphology and ultrastructure of the BA-Fe₃O₄@Lip.

From figure 3, it can be observed that the structure of BA-Fe₃O₄@Lip containing Fe₃O₄ nanoparticles shows spherical structures without any inner water pool.

**Cell viability assessment by the means of AlamarBlue assay**

As shown in figure 4, the viability of the healthy JB6 CI 41-5a cells exposed to the lowest concentration of the liposomal structures (5 µM) was not significantly affected.

![SEM-EDAX analysis of BA-Fe₃O₄@Lip.](image1)

![Cell viability of mice epidermis JB6 CI 41-5a cells after stimulation with test samples (5 and 25 µM). The data are presented as cell viability percentage normalized to control cells (no stimulation).](image2)
BA expressing the most damaging effect. However, the highest concentration of compounds (25μM) induced a reduction of viable JB6 Cl 41-5a cell population, showing a viability percentage around 75-83%. After 48 h, all samples induced a slight increase (about 4-5%) of JB6 Cl 41-5a viability rate, comparative with the cell viability rate expressed after 24 h post-stimulation.

The blank liposomal structures (Lip, Fe₃O₄@Lip) manifested cell viability above 60% in the case of both cell lines, after treatment with the highest concentration (25μM). The effect induced by test compounds respected almost the same tendency of cell viability decrease on both melanoma cell lines (B164A5 and A375), yet A375 cells seemed to be more sensitive. Present data showed that the highest concentration (25μM) of BA-Fe₃O₄@Lip caused a significant inhibitory activity on both melanoma cell lines, displaying a viability rate of 24% on B164A5 cells versus 7.80% viability percentage in the case of A375 cells, after 24 h post-stimulation. However, both cell lines (A375, B164A5) manifested a slight cell viability growth after 48h, B164A5 cells expressing a viability percentage of 38%, compared to a viability rate of 31.5% expressed by A375 cells. The trend of cell viability growth after 48h of stimulation was observed by almost all test samples, except BA which exhibited a higher cytotoxic activity after 48h, compared with the one recorded after 24h post-treatment (fig. 5).

Thus, we assume that the cytotoxic effect induced by BA-Fe₃O₄@Lip may be due to BA embedded in the magnetoliposome structure. Association of the BA well-known cytotoxic potential with the applications IOMNPs in biotechnology (hyperthermia, drug controlled release) can lead to a synergistic anti-tumor activity.

Cell morphology after treatment with test samples

The most severe morphological alterations of the test cell lines (JB6 Cl 41-5a, B164A5, A375) were recorded 24h post-stimulation and are depicted in figures 6-8.

The healthy mice epidermis JB6 Cl 41-5a cells exposed to the lowest concentration of liposomal samples (5 mM) presented normal morphological aspects, epithelial-like with a confluence above 90%. However, the cells treated with BA at the same concentration of 5 M exhibited slight morphological alterations, indicated by the red arrows in figure 6.

The cells stimulated with test samples at the highest tested concentration (25 mM) induced some morphological changes, but still no more substantial than those induced by the same concentration of BA, used as positive control.

As shown in figure 7 and figure 8, both melanoma cell lines (B164A5 and A375 cells) manifested no altered morphological aspects after treatment with the lowest concentration of test compounds (5 mM). The effect induced by test compounds respected almost the same tendency of cell viability decrease on both melanoma cell lines (B164A5 and A375), yet A375 cells seemed to be more sensitive. Present data showed that the highest concentration (25μM) of BA-Fe₃O₄@Lip caused a significant inhibitory activity on both melanoma cell lines, displaying a viability rate of 24% on B164A5 cells versus 7.80% viability percentage in the case of A375 cells, after 24 h post-stimulation. However, both cell lines (A375, B164A5) manifested a slight cell viability growth after 48h, B164A5 cells expressing a viability percentage of 38%, compared to a viability rate of 31.5% expressed by A375 cells. The trend of cell viability growth after 48h of stimulation was observed by almost all test samples, except BA which exhibited a higher cytotoxic activity after 48h, compared with the one recorded after 24h post-treatment (fig. 5).

Fig. 5. Cell viability of murine melanoma - B164A5 cells and human melanoma - A375 cells after stimulation with test samples (5 and 25 µM). Bar graphs are expressed as cell viability percentage normalized to control cells (no stimulation).

Fig. 6. Morphological aspects of mice epidermis JB6 Cl 41-5a cells stimulated with test samples (5 and 25 µM), 24h post-treatment.

Fig. 7. Morphological aspects of murine melanoma - B164A5 cells stimulated with test samples (5 and 25 µM), 24h post-treatment.
concentration (5 µM) of test compounds. Increasing the concentration at 25 µM, severe morphological changes were observed, especially after treatment with the compound of interest (BA-Fe₃O₄@Lip). In this case, the cytotoxic activity manifested by the highest concentration of test samples was not exceeded by the effect of BA treatment. Still, human melanoma A375 cells seemed more sensitive, a lot of apoptotic cells being observed after treatment with Fe₃O₄@Lip and BA, data supported by cell viability assessment.

A similar magnetoliposome system was also developed by Kulshrestha and collaborators, having paclitaxel as active substance and citric acid coated Fe₃O₄ NPs, as a magnetic compound. The magnetoliposomal platform expressed good cytotoxic activity on HeLa cells and great potential for drug delivery application and hyperthermia [23]. Clayes and co-workers reported nanosized 5-fluorouracil-loaded magnetoliposomes with good in vitro compatibility and features for creating hyperthermic conditions to release 5-fluorouracil from the thermosensitive magnetoliposome structure [25]. Beside hyperthermia and drug controlled release, recent studies reported the efficacy of magnetoliposomes as contrast agents: in a rat model of liver ischemia-reperfusion [26] or in a diabetic rat model for labeling pancreatic islets [27].

In a comprehensive literature review, Allen and Cullis explained the importance of including cholesterol in the liposome structure, considering that this compound improves the phospholipid bilayer's stiffness, thereby reducing drug leakage from the liposomes [28]. Moreover, the same study presented the advantages of using ammonium sulfate for obtaining remote loading of drugs within liposomes, by transforming the drugs in weak bases or weak base prodrugs. Other studies discussed the importance of using PEGylated liposomes to enhance drug delivery with good in vitro encapsulation efficiency [29], along with a better stability [30]. The synthesis process employed in this study respected all the aforementioned details described in the literature to achieve an improved formula of magnetoliposomes.

**Conclusions**

The experiments conducted in this study provide basic evidence of the massive potential of magnetoliposomes as thermally controlled structures, displaying selective cytotoxicity on murine melanoma B16455 cells and human melanoma A375 cells, showing slight inhibitory activity on mice epidermis JB6 Cl 41-5a cells viability. The magnetoliposome platform may offer a multitude of multifunctional biomedical applications, such as combining hyperthermia with drug controlled release. Nevertheless, *in vitro* and *in vivo* experiments should continue to be performed.

**Acknowledgment:** This study was financially supported from a grant offered by Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania for doctoral research project, awarded by Claudia Farcas, contract no 1300/23.13.2017; 306617/01.02.2018.

**References**

1. GEORGEOUSU, D., JUNG, M., OREN, B., SCHMID, T., DEHELEAN, C., MUNTEAN, D., BRUNE, B. Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol. Chem., 394(6), 2013, p. 773–781. DOI 10.1515/hbz-2013-0106
2. FULDA, S. Betulinic acid: A natural product with anticancer activity. Mol. Nutr. Food Res., 53, 2009, p. 140 – 146. DOI 10.1002/mnfr.200700491
3. MULLAUER, F.B., KESSLER J.H., MEDEMA J.P. Betulinic acid, a natural compound with potent anticancer effects. Anti-Cancer Drugs, 21, 2010, p. 215 – 227. DOI: 10.1097/CAD.0b013e3283357c62.
4. ZUCO, V., SUPINO, R., RIGHETTI, S.C., CLERIS, L., MARCHESI, E., CARLO, G.P., FORMELLI, F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Letters, 175, 2002, p. 17–25. https://doi.org/10.1016/S0304-3835(01)00718-2
5. CICHIEWSICZ, R.H., KOUIZ, S.A. Chemistry, Biological Activity, and Chemotherapeutic Potential of Betulinic Acid for the Prevention and Treatment of Cancer and HIV Infection. Med. Res. Rev., 24 (1), 2004, p. 90–114. DOI 10.1002/med.10053
6. YOGEESWARI, P., SRIRAM, D. Betulinic acid and its derivatives: a review on their biological properties. Curr. Med. Chem., 12(6), 2005, p. 567–56.
7. MOGHADDAM, M.G, AHMAD, F.B.H., SAMZADEH-KERMANNI, A. Biological Activity of Betulinic Acid: A Review. Pharmacology & Pharmacy, 3, 2012, p. 119–123. http://dx.doi.org/10.4236/pp.2012.32018.
8. MUKHERJI, E., JACQUES, M., RAJENDRAN, P., SIDDIQUI, M.J.A., SRIVASTAVA, S.K., VARDAH, A., BURMAN, A.C. Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg. Med. Chem. Lett., 14, 2004, p. 2181–2184. doi:10.1016/j.bmcl.2004.02.044.
9. DEHELEAN, C.A., FEFLSEA, S., GANTTA, S., AMMII, M. Antiangiogenic effects of betulinic acid administered in nanoemulsion formulation using chloroalkanol membrane assay. J. Biomed. Nanotechnol., 7(2), 2011, p. 317–24.
10. ZHU, L., YI, X., ZHAO, J., YUAN, Z., WEN, L., POZNIAK, B., OMBINSKA-MRUKOWICZ, B., TIAN, Y., TAN, Z., WU, J., YI, J. Betulinic acid attenuates dexamethasone-induced oxidative damage through the JNK-P38 MAPK signalling pathway in mice. Biomed. Pharmacother. 103, 2018, p. 499–508. doi: 10.1016/j.biopharm.2018.04.073.
11. WANG, H.M., OICCA, C.M., WENZ, G. A Comparison Investigation on the Solubilization of Betulin and Betulinic Acid in Cyclodextrin Derivatives. Nat. Prod. Res., 2012, p. 289–291.
12. PERIASAMY, G., TEKETELEW, G., GEBRELIBANOS, M., SINTAYEHU, B., OBMINSK A-MRUKOWICZ, B., TIAN, Y., ZHAO, J., WU, J., YI, J. Betulinic acid and its derivatives as anti-cancer agent:A review. Arch. Pharma. Chemotherapeutic Potential of Betulinic Acid for the Prevention and Treatment of Cancer and HIV Infection. Med. Res. Rev., 24 (1), 2004, p. 90–114. DOI 10.1002/med.10053
13. SOICA, C., DANCIU, C., SAVOIU-BALINT, G., BORCAN, F., AMBRUS, R., ZUPKO, I., BOJIN, F., CORICOVAC, D., CIURLEA, S., AVRAM, S., DEHELEAN, C.A., OLARIU, T., MATUSZ, P. Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B16455 cells. Int. J. Mol. Sci., 15, 2014, p. 47-5.
14. NICOLAU, M., GHIMAI, R.M., VOICIU, M., MIOR, M., DUSE, A.O., ROMAN, R., AMBRUS, R., ZUPKO, I., MOACA, E.A., CORICOVAC, D.E., FARCAS, C., RACOVICEANU, R., DANCIU, R., MUNTEAN, D., BRUNE, B. Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol. Chem., 394(6), 2013, p. 773–781. DOI 10.1515/hbz-2013-0106.
C., DEHELEAN, C.A., SOICA, C. Cocrystal Formation Synthesis, Physico-Chemical Assessment, Antioxidant, and Antiproliferative Activity. Front. Chem., 7, 2019, p. 92. doi: 10.3389/fchem.2019.00092.

15. LIU, Y., GAO, D., ZHANG, X., LIU, Z., DAI, K., JI, B., WANG, Q., LUO, L., Antitumor drug effect of betulinic acid mediated by polyethylene glycol modified liposomes. Mater. Sci. Eng. C. Mater. Biol. Appl., 64, 2016, p. 124-132. doi: 10.1016/j.msce.2016.03.080.

16. TAN, J.M., KARTHIKAVAN, A., ABG GANI, S., FAKURAZI, S., HUSSEIN, M. Biocompatible polyesters coated on carboxylated nanotubes functionalized with betulinic acid for effective drug delivery. J. Mater. Sci. Mater. Med., 27, 2016. doi: 10.1007/s10856-015-5635-8.

17. SANTHOSH, P.B., DRASLER, B., DROBNE, D., KREFT, M.E., KRALJ, S., MAKOVEC, D., ULRIH, N.P., Effect of superparamagnetic iron oxide nanoparticles on fluidity and phase transition of phosphatidylcholine liposomal membranes. Int. J. Nanomedicine., 10, 2015, p 6089-103. doi: 10.2147/ijn.2014.89679

18. GUPTA, A.K., GUPTA, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials., 26, 2005, p. 3995-4021.

19. MOACA, E.A., CORICOVAC, E.D., SOICA, C.D., PINZARU, I.A., PACURARIU, C.S., DEHELEAN C.A. Iron Ores and Iron Oxide Materials. Preclinical Aspects on Magnetic Iron Oxide Nanoparticles and Their Interventions as Anticancer Agents: Enucleation, Apoptosis and Other Mechanism. IntechOpen, Edited by Volodymyr Shatokha, London, 2018, p. 229-247

20. MAHMOUDI, M., SANT, S., WANG, B., LAURENT, S., SEN, T. Superparamagnetic iron oxide nanoparticles (SPIONS): development, surface modification and applications in chemotherapy. Adv. Drug. Deliv. Rev., 63, 2011, p 24-46. doi: 10.1016/j.addr.2010.05.006.

21. JANOS, R., TACULESCU A., PACURARIU, C., LAZAU, I. Solution Combustion Synthesis and Characterization of Magnetite, Fe3O4, Nanopowders. J. Am. Ceram. Soc., 2012, p 1-5.

22. HE, Y., ZHANG, L., ZHU, D., SONG, C. Design of multifunctional magnetic iron oxide nanoparticles/miRNAxtron-mediator liposomes for both magnetic resonance imaging and targeted cancer therapy. Int. J. Nanomedicine., 9, 2014, p 4055-4066.

23. KULSHRESTHA, P., GOOGI, M., BAHADUR, D., BANEKJEE, R. In gnetobioliposomes for combined chemotherapy and hyperthermia. Colloids Surf. B. Biointerfaces., 96, 2012, p 1-7.

24. MOACA, E.A., FARCAS, C., GHITU, A., CORICOCOVAC, D., POPOVICI, R., CARABE-MEITA, N.L., ARDELEAN, F., ANTAL, D.S., DEHELEAN, C., AVRAM, S. A Comparative Study of Melissa officinalis Leaves and Stems Ethanolic Extracts in terms of Antioxidant, Cytotoxic, and Antiproliferative Potential. Evid. Based. Complement. Alternat. Med., 2018. doi: 10.1155/2018/7860456.

25. CLARES, B., BIEDMA-ORTIZ, R.A., SAEIZ-FERNANDEZ, E., PRADOS, J.C., MELGUIZO, C., CABEZA, L., ORTIZ, R., ARIAS, J.L. Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. Eur. J. Pharm. Biopharm., 85, 2013, p. 329-338. https://doi.org/10.1016/j.ejpb.2013.01.028.

26. MARTINS, M.B., CORVO, M.L., MARCELINO, P., MARINHO, H.S., FEIO, G., CARVALHO, A. New long circulating circulating magnetoliposomes as contrast agents for detection of ischemia-reperfusion injuries by MRI. Nanomedicine. 10, 2014, p 207-14. doi: 10.1016/j.nano.2013.06.008.

27. GARCIA RIBEIRO R.S., GYSEMANS, C., DA CUNHA, J.P.M.C.M., MANSHIAN, B.B., JIRAK, D., KRIZ, J., GALLO, J., BANOBRE-LOPEZ, M., STRUYS, T., DE CUYPER, M., MATHIEU, C., SOENEN, S.J., GSELL, W., HIMMELREICH, U. Magnetoliposomes as Contrast Agents for Longitudinal in vivo Assessment of Transplanted Pancreatic Islets in a Diabetic Rat Model. Sci Rep., 8, 2018. doi: 10.1038/s41598-018-29136-9.

28. ALLEN, T.M., CULLIS, P. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug. Deliv. Rev., 65, 2013, p. 36-48. doi: 10.1016/j.addr.2012.09.037.

29. ZHAO, T., LIU, Y., GAO, Z., GAO, D., LI, N., BIAN, Y., DAI, K., LIU, Z. Self-assembly and cytotoxicity study of PEG-modified ursolic acid liposomes. Mater. Sci. Eng. C. Mater. Biol. Appl., 53, 2015, p. 196-203. doi: 10.1016/j.msec.2015.04.022.

30. GAO, D., TANG, S., TONG, Q. Oleanolic acid liposomes with polyethylene glycol modification; promising antitumor drug delivery. Int. J. Nanomedicine., 7, 2012, p 3517-26. doi: 10.2147/IJN.S31725.

Manuscript received: 11.05.2019